FGEN实时信号 | 通过Getagraph.com最大化利润

购买 107677 min ago

@ $2.26

发出时间: 15 Feb 2024 @ 04:55

回报率: -49.78%

上一信号: Feb 15 - 04:23

上一信号: 出售

回报率: -2.38 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 23:33):

Stats
今日成交量	479 388
平均成交量	2.45M
市值	112.90M
EPS	$0 ( 2024-02-26 )
下一个收益日期	( $0 ) 2024-05-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.390
ATR14	$0.00800 (0.70%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-22	Adib Deyaa	Sell	0	Common Stock
2024-04-22	Adib Deyaa	Sell	300 000	Stock Option (Right to Buy)
2024-03-22	Wettig Thane	Sell	782	Common Stock
2024-03-07	Wettig Thane	Buy	50 000	Common Stock
2024-03-06	Graham Juan	Buy	781	Common Stock

INSIDER POWER
64.62
Last 100 transactions
Buy: 2 904 321 \| Sell: 578 976

音量相关性

長: 0.32 (neutral)

短: 0.78 (moderate)

Signal:(44.8) Neutral

FibroGen Inc 相关性

10 最正相关
FCBP	0.909
SMMT	0.904
CCOI	0.901
FGM	0.897
YQ	0.893
FEP	0.89
EUFN	0.889
BNIXU	0.887
CID	0.887
NIU	0.886

10 最负相关
PCRX	-0.904
SLDP	-0.891
MARK	-0.887
PFBI	-0.887
WKSP	-0.885
RCMT	-0.884
NTLA	-0.882
ONDS	-0.875
LARK	-0.875
RDHL	-0.869

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

FibroGen Inc 相关性 - 货币/商品

-0.09
( neutral )

-0.25
( neutral )

0.00
( neutral )

0.73
( moderate )

0.29
( neutral )

FibroGen Inc 财务报表

Annual	2023
营收:	$147.75M
毛利润:	$128.90M (87.24 %)
EPS:	$-2.92

FY	2023
营收:	$147.75M
毛利润:	$128.90M (87.24 %)
EPS:	$-2.92

FY	2022
营收:	$140.73M
毛利润:	$120.45M (85.59 %)
EPS:	$-3.15

FY	2021
营收:	$235.31M
毛利润:	$222.44M (94.53 %)
EPS:	$-3.13

Financial Reports:

No articles found.

FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.